Market news
As previously announced on July 14, 2026, Avere and NextCure, Inc. have entered into a definitive merger agreement for an all-stock transaction. The $500 million Private Placement consists of common stock and pre-funded warrants to purchase common stock. Participants in the Private Placement included Venrock Healthcare Capital Partners, General...
BELTSVILLE, Md., Aug. 06, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel therapies to treat cancer, today provided a business update and reported...
Detailed price information for Nextcure Inc (NXTC-Q) from The Globe and Mail including charting and trades.
NextCure will merge with Avere in a $320 million exchange to advance oral IL-23 therapy AVR-001 and list the combined company as AVRX.
Gainers NextCure (NASDAQ:NXTC) stock increased by 201.4% to $6.57 during Tuesday's regular session. The market value of their outstanding shares is at $7.8 million. Shuttle Pharmaceuticals (NASDAQ:SHPH) shares
Set to go public via a reverse merger, Avere has licensed from a prolific Chinese drugmaker rights to a potential threat to medicines like Skyrizi and Icotyde.
This is the newest page. Registered accounts read further back.